Financial Performance - The company's operating revenue for the third quarter was ¥123,298,080.72, a decrease of 38.69% compared to the same period last year[4] - The total profit for the quarter was -¥19,173,115.50, reflecting a decline of 254.11% year-on-year[4] - The net profit attributable to shareholders was -¥12,428,911.08, a significant decrease of 7,912.82% compared to the previous year[4] - The net profit excluding non-recurring gains and losses was -¥14,856,098.85, with a year-to-date decrease of 1,201.31%[4] - The basic earnings per share for the quarter was -¥0.043, a decrease of 178.47% compared to the same period last year[5] - The diluted earnings per share for the quarter was also -¥0.043, reflecting a similar decline of 178.47% year-on-year[5] - The weighted average return on equity was -2.43%, a decrease of 2.45 percentage points compared to the previous year[5] Assets and Liabilities - Total assets at the end of the quarter were ¥2,993,661,485.46, down 6.88% from the end of the previous year[5] - The equity attributable to shareholders was ¥517,715,741.11, a slight decrease of 0.20% compared to the previous year[5] - The company's total liabilities as of September 30, 2025, were CNY 2,287,335,577.61, compared to CNY 2,506,452,041.54 at the end of 2024, indicating a reduction of about 8.7%[19] - The total assets of the company decreased to CNY 2,993,661,485.46 as of September 30, 2025, down from CNY 3,214,984,288.09 at the end of 2024, indicating a decline of approximately 6.9%[19] Cash Flow - The cash flow from operating activities for the year-to-date was ¥147,211,536.83, an increase of 39.90%[4] - The company's cash and cash equivalents decreased to CNY 145,924,090.03 as of September 30, 2025, from CNY 178,048,527.26 at the end of 2024, reflecting a decline of approximately 18.0%[17] - The total cash and cash equivalents at the end of the period decreased to CNY 78,681,406.32 from CNY 115,160,450.82, a decline of 31.7%[29] - The company experienced a net cash outflow from financing activities of CNY -101,406,021.68, compared to CNY -23,938,126.12 in the previous year[29] - The investment activities generated a net cash outflow of CNY -67,463,775.81, compared to CNY -61,213,199.64 in the same period last year[29] Shareholder Information - The company reported a total of 21,713,000 common shares outstanding at the end of the reporting period[12] - Major shareholder Luo Weiguo holds 37,251,829 shares, representing 12.84% of total shares, with 22,000,000 shares pledged and 14,375,524 shares frozen[12] - Major shareholder Shi Dongwei holds 32,338,800 shares, representing 11.15% of total shares, with 29,000,000 shares pledged and 3,181,856 shares frozen[12] - Shenzhen Zeyuan Private Securities Fund Management Co., Ltd. holds 22,000,000 shares, representing 7.58% of total shares[12] - The company has undergone a change in actual control, with Luo Weiguo becoming the sole actual controller after the termination of the concerted action agreement with Shi Dongwei[14] - As of August 25, 2025, Shi Dongwei has irrevocably agreed to waive all voting rights associated with his 32,338,800 shares[14] - The report indicates that there are no significant changes in the shareholding structure of the top 10 shareholders[14] - The total number of shares held by the top 10 unrestricted shareholders remains unchanged[14] Future Plans and Investments - The company plans to issue up to 71,028,297 A-shares to Shanghai Daoyun Asset Management Co., Ltd., raising a total of no more than CNY 465.2353 million, which will be used for working capital and debt repayment[15] - The company is in the process of issuing A-shares, pending approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission[15] Research and Development - Research and development expenses rose to CNY 11,407,398.61, an increase of 72.5% compared to CNY 6,607,811.49 in the same period last year[24] Financial Expenses - The company reported a significant increase in financial expenses, totaling CNY 31,050,606.74, compared to CNY 9,137,237.34 in the previous year, marking a rise of 239.5%[24] Overall Performance - For the first three quarters of 2025, total operating revenue was CNY 535,601,036.79, down approximately 14.2% from CNY 624,472,530.50 in the same period of 2024[22] - Total operating costs for the first three quarters of 2025 were CNY 567,048,150.94, a decrease of about 4.7% compared to CNY 594,720,864.52 in the previous year[22] - The net profit for the first three quarters of 2025 is CNY 10,668,058.84, a decrease of 60.9% compared to CNY 27,281,131.61 in the same period of 2024[24] - The total revenue from operating activities for the first three quarters of 2025 is CNY 765,216,638.76, down from CNY 834,739,497.39 in 2024, representing a decline of 8.3%[27] - The basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.0031, compared to CNY 0.0220 in the same period of 2024[24]

Core Viewpoint - Tianyu Bio reported a significant decline in revenue and net profit for the third quarter and the first three quarters of the year, indicating potential challenges in its business operations [1] Financial Performance - The company's revenue for the third quarter was 123 million yuan, a year-on-year decrease of 38.69% [1] - The net profit for the third quarter showed a loss of 12.43 million yuan, representing a decline of 7,912.82% [1] - For the first three quarters, the total revenue was 536 million yuan, down 14.23% year-on-year [1] - The net profit for the first three quarters was a loss of 1.61 million yuan, which is a decline of 152.22% [1]

Core Viewpoint - Tianyu Biological (603717) announced that the company has no overdue guarantees [1] Summary by Relevant Sections - Company Announcement - Tianyu Biological confirmed in a recent announcement that there are no overdue guarantees [1]

累计担保情况 | 对外担保逾期的累计金额（万元） | / | | --- | --- | | 截至本公告日上市公司及其控股子 | | | 公司对外担保总额（万元） | 109,273.48 | | （实际发生的担保余额，不含本次） | | | 对外担保总额占上市公司最近一期 | 210.65 | | 经审计净资产的比例（%） | 对外担保总额超过最近一期经审计净资 | | 产 | 100% | | | □担保金额超过上市公司最近一期经审计 | | 特别风险提示（如有请勾选） | 净资产 50% | | | □对合并报表外单位担保金额达到或超过 | | | 最近一期经审计净资产 30%的情况下 | | | 对资产负债率超过 70%的单位提供担保 | 1 证券代码：603717 证券简称：天域生物 公告编号：2025-100 天域生物科技股份有限公司 关于公司 2025 年度对外担保预计的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 宜昌天域农牧 ...

天域生物科技股份有限公司 关于变更保荐机构及保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603717 证券简称：天域生物 公告编号：2025-099 特此公告。 天域生物科技股份有限公司董事会 经中国证券监督管理委员会《关于核准天域生态环境股份有限公司非公开发 行股票的批复》（证监许可[2021]101 号），天域生物科技股份有限公司（以下 简称"公司"，曾用名"天域生态环境股份有限公司"）向特定对象发行人民币 普通股（A 股）股票 4,835 万股（以下简称"前次向特定对象发行"），并已于 2021 年 7 月完成发行。中德证券有限责任公司（以下简称"中德证券"）担任 公司前次向特定对象发行的保荐机构，法定持续督导期至 2022 年 12 月 31 日止。 因前述期限届满后公司募集资金尚未使用完毕，中德证券继续履行募集资金相关 的持续督导职责。 公司于 2025 年 08 月 25 日召开第四届董事会第四十三次会议，并于 2025 年 09 月 11 日召开 2025 年第三次临时股东大会，审 ...

Core Insights - The aquaculture sector experienced a slight decline of 0.08% on October 24, with Xiaoming Co. leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Aquaculture Sector Performance - Yisheng Co. (002458) saw a closing price of 8.85, with an increase of 2.67% and a trading volume of 150,400 shares, totaling a transaction value of 134 million yuan [1] - Shengnong Development (002299) closed at 16.28, up 1.12%, with a trading volume of 136,800 shares and a transaction value of 222 million yuan [1] - Other notable performances include: - ST Tianshan (300313) at 8.43, up 0.60% [1] - Jinjidun Agricultural (000048) at 17.03, up 0.53% [1] - Muyuan Foods (002714) at 48.86, up 0.31% [1] - Xiaoming Co. (300967) led the decline with a closing price of 21.20, down 3.02% [2] Capital Flow Analysis - The aquaculture sector saw a net outflow of 153 million yuan from institutional investors, while retail investors contributed a net inflow of 11.67 million yuan [2] - Notable capital flows include: - Luoniushan (000735) with a net inflow of 5.14 million yuan from institutional investors [3] - Yike Foods (301116) with a net outflow of 1.90 million yuan from institutional investors [3] - Yisheng Co. (002458) experienced a net outflow of 2.22 million yuan from institutional investors [3]

Core Insights - The aquaculture sector experienced a slight increase of 0.28% on October 23, with Xiaoming Co. leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Aquaculture Sector Performance - Xiaoming Co. (300967) closed at 21.86, up 2.82% with a trading volume of 105,300 shares and a transaction value of 230 million [1] - Tianyu Biological (603717) closed at 9.17, up 2.12% with a trading volume of 152,700 shares and a transaction value of 140 million [1] - Other notable performers include Xiangjia Co. (002982) up 1.76%, Minhe Co. (002234) up 1.73%, and Xinwufeng (600975) up 1.57% [1] Capital Flow Analysis - The aquaculture sector saw a net inflow of 25.81 million from institutional investors, while retail investors contributed a net inflow of 4.57 million [2] - Major stocks like Jingji Zhino (000048) experienced a significant net outflow of 29.90 million from speculative funds [3] - Muyu Co. (002714) had a net inflow of 43.02 million from institutional investors, but also saw a net outflow of 26.25 million from speculative funds [3]

发行人声明 1、本公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不 存在虚假记载、误导性陈述或重大遗漏，并对本预案内容的真实性、准确性、完 整性承担个别和连带的法律责任。 2、本预案按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司证券发行注册管理办法》等法律、法规及规范性文件的要求编制。 证券代码：603717 证券简称：天域生物 天域生物科技股份有限公司 2025 年度向特定对象发行 A 股股票预案 （修订稿） 二〇二五年十月 3、本次向特定对象发行股票完成后，公司经营与收益的变化，由公司自行 负责；因本次向特定对象发行股票引致的投资风险，由投资者自行负责。 4、本预案是公司董事会对本次向特定对象发行股票的说明，任何与之相反 的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机关对于本次向特定对象发行股票相关事 项的实质性判断、确认、批准或核准，本预案所述本次向特定对象发行股票相关 事项的生效和完成尚待上海证券交易所审核通过并经中国证券监督管理委员会 同意注册后方可实施。 1 特别提示 本部分所 ...

证券代码：603717 证券简称：天域生物 天域生物科技股份有限公司 注：1、本报告所引用的财务数据和财务指标，如无特殊说明，指合并报表口径的财务 数据和根据该类财务数据计算的财务指标。2、除特别说明外，本报告若出现部分合计数与 各加数直接相加之和在尾数上存在差异，系四舍五入所致。 2025 年度向特定对象发行 A 股股票 方案论证分析报告 （修订稿） 二〇二五年十月 | 释 义 . | | --- | | 一、本次发行的背景和目的 . | | (一) 本次发行的背景 | | (二) 本次发行的目的 | | 二、本次发行证券及其品种选择的必要性 . | | (一) 本次发行证券的品种 . | | (二) 本次发行证券品种选择的必要性 | | 三、本次发行对象的选择范围、数量和标准的适当性 ………………………………………… b | | (一) 本次发行对象选择范围及数量的适当性 . | | (二) 本次发行对象标准的适当性 | | 四、本次发行定价的原则、依据、方法和程序的合理性……………………………………… 6 | | (一) 本次发行定价的原则和依据 | | (二) 本次发行定价的方法和程序 | | 五、本 ...

证券代码：603717 证券简称：天域生物 公告编号：2025-097 及相关文件修订情况说明的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）于 2025 年 08 月 25 日召 开第四届董事会第四十三次会议、第四届监事会第三十六次会议，于 2025 年 09 月 11 日召开 2025 年第三次临时股东大会分别审议通过了 2025 年度向特定对象 发行 A 股股票（以下简称"本次发行"）等相关议案。 鉴于公司已根据《关于新<公司法>配套制度规则实施相关过渡期安排》等法 规要求完成了监事会取消设置、"股东大会"表述调整为"股东会"等事项，为 使本次发行预案等文件中关于公司治理结构的表述符合公司最新设置情况，公司 于 2025 年 10 月 22 日召开了第五届董事会第二次会议，审议通过《关于<公司 2025 年度向特定对象发行 A 股股票预案（修订稿）>的议案》等相关议案。为便 于投资者查阅，现将本次修订的主要内容说明如下： 一、公司 2025 年度向特定对象发行 A 股股 ...